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Abstract
Background: Desmoplasia in medulloblastoma is often diagnosed in adult patients and was repeatedly associated
with improved results. Today, all medulloblastoma patients receive intensive multimodal treatment including
surgery, radiotherapy and chemotherapy. This study was set up to investigate treatment outcome and prognostic
factors after radiation therapy in patients with desmoplastic medulloblastomas.
Methods: Twenty patients treated for desmoplastic medulloblastoma in the Department of Radiation Oncology at
the University of Heidelberg between 1984 and 2007 were included. Data were collected retrospectively. Tumor
resection was performed in all patients. All patients underwent postsurgical radiotherapy (RT). Two patients
underwent whole brain radiotherapy (WBRT), and 18 patients received craniospinal irradiation (CSI). In all patients,
an additional boost was delivered to the posterior fossa. The median dose to the whole brain and the craniospinal
axis was 35.2 Gray (Gy), and 54.4 Gy to the posterior fossa. Fourteen patients received chemotherapy, including
seven who were treated with combined radiochemotherapy and twelve who received adjuvant chemotherapy.
Statistical analysis was performed using the log-rank test and the Kaplan-Meier method.
Results: Median follow-up was 59 months. Overall (OS), local (LPFS) and distant progression-free survival (DPFS)
was 80%, 71.2%, and 83.3% at 60 months. Patients who suffered from local or distant relapses had significantly
worse outcome. Five patients died from recurrent medulloblastoma. Treatment-associated toxicity was acceptable.
Conclusions: Multimodal approaches with surgical resection followed by chemoirradiation achieved high response
rates with long OS in desmoplastic medulloblastoma patients. Staging parameters expected to predict for poor
prognosis did not significantly influence outcome. However, success of any first line regimen had strong impact on
disease control, and remission was achieved in no patient with relapsing disease. Multimodal concepts must be
evaluated in further clinical trials.
Background
Medulloblastoma is the most common and most malig-
nant embryonal tumor of the pediatric central nervous
system (CNS). It is believed to originate from neuroe-
pithelial cells, lining the roof of the fourth ventricle [1].
Different histological subtypes of varying neuronal dif-
ferentiation have been described, and among these des-
moplastic medulloblastoma, known for its nodular
architecture, has been discussed controversially with
respect to its impact on therapy response and outcome.
Most medulloblastoma patients are diagnosed between
five and ten years of age, accounting for 25% of all
pediatric brain tumors [2]. Medulloblastomas occur
rarely in adolescents and adults, however about 1% of
all non-pediatric brain tumors are identified as primitive
neuroectodermal tumors (PNET), among which medul-
loblastoma is the major subgroup [3,4]. In this popula-
tion, a clear distinction must be made between
infratentorial and supratentorial medulloblastomas, in
the latter location also referred to as PNET, which
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poorer outcome due to their rapidly invasive growth [5].
Early locoregional infiltration has been shown to com-
promise local control rates and predispose for systemic
spread of disease via the neuraxis in case of supratentor-
ial location [6].
Lateral tumor location, desmoplastic histology variant,
and recurrence of disease after longer time periods are
only some of the main distinguishing features between
medulloblastoma in adults and in children [7].
Continuously evolving therapeutical strategies includ-
ing adjuvant RT and extensive concomitant and adju-
vant chemotherapy have helped to substantially improve
survival rates after surgical resection in children [8]. In
adults however, no optimal standard treatment regimen
has been developed, most likely due to small patient
numbers. This has led to numerous reports on indivi-
dual treatment strategies for non-pediatric patients, in
which either combination or adjuvant addition of
chemotherapy was abandoned or dosage and fractiona-
tion scheme of irradiation were altered. Different histo-
logical patterns, sites of tumor location and recurrence
among non-pediatric patients are poorly understood.
Their impact on response and outcome has been
addressed several times, yet remains unclear until now
[9]. In the past, most centers have treated adult patients
in analogy to pediatric multidisciplinary treatment pro-
tocols including extensive neurosurgical resection, CSI
and chemotherapy. However, it is known that toxicitiy
profiles may vary substantially between children and
adults [10]. Therefore, multidisciplinary treatment
approaches are currently being investigated in an obser-
vational study conducted by the Neurooncology Group
of the German Cancer Society which recently started
accrual (NOA-07 Trial, http://www.neuroonkologie.de).
Progression-free survival rates (PFS) reported in the
literature vary between treatment strategies and centers
and are reported to be between 35% and 95% at five
years; a number of risk factors have been identified to
potentially influence treatment response and allow for
outcome predictions [11,12]. Risk-adapted therapy
approaches, however, require clear identification of
prognostic factors, which among others include extent
of surgery, initial disease dissemination, locoregional
infiltration and age at primary diagnosis [13].
The desmoplastic histology variant was repeatedly
described to be indicative of low risk but its significance
as a potential predictor of good response still remains
unclear [11,14,15]. In children younger than three years
in whom no adjuvant radiotherapy is administered,
desmoplastic histology was associated with PFS as high
as 85% after ten years, opposed to classic histology with
34% [16], questioning the necessity for radiation in des-
moplastic histology variant. Within a group of adult
medulloblastoma, higher percentages of desmoplasia
must be expected than in previous, mostly pediatric
studies, ranging from 25% to 40% [7,17]. Since the
German Neurooncology Group (NOA) has initiated a
new study focusing upon medulloblastomas in adults
(NOA-07 Trial), once again attention must be paid to
the impact of desmoplasia on therapy outcome, since
this subtype must be expected more frequently in the
adult population. Prognostic factors within the group of
desmoplastic medulloblastoma patients have not been
addressed to date. Recently, few molecular DNA-based
parameters such as 6q-deletion were identified to
predict for good prognosis in medulloblastoma in
general including desmoplastic histology [18]. However,
no stratification of these patients into risk adapted ther-
apy groups has been established. For the establishment
of high and low risk therapy groups, several factors of
potential threat can be considered, some of which are
considered also in classical medulloblastoma [9].
In the present analysis, we evaluate outcome in the
rare group of patients with histologically confirmed
desmoplastic medulloblastomas treated within multi-
disciplinary concepts.
Methods
This project was performed in accordance with institu-
tional ethical policies. No ethical approval was neces-
sary, because all data were collected retrospectively from
an institutional patient database and tumor registry.
They were collected anonymously using a uniform
retrieval code ("desm. mb”) for data acquisition.
Between 1984 and 2007, 20 patients with histologically
confirmed desmoplastic medulloblastomas were treated
at the Department of Radiation Oncology in Heidelberg,
Germany. Median follow-up time was 58.5 months
(range 5 - 254 months). Two patients were lost to
further follow-up after 5 and 60 months, respectively.
Patient characteristics
Thirteen patients were male (65%), and 7 were female
(35%). Median age at primary diagnosis was 24 years
(range 3-50 years). The youngest patient was three years
old. Seven patients were 18 years of age or younger
(35%), while 13 patients (65%) were older than 18 years,
with 11 patients being older than 21 years (55%).
Surgery and histopathological findings
In order to relieve ventricle obstruction, to obtain tissue
for neuropathological analysis and to reduce tumor
volume by complete or partial tumor resection, all
patients underwent neurosurgical resection before RT.
In 13 patients a complete tumor resection was achieved
(65%), while in 7 patients a subtotal tumor resection
was performed (35%). Extent of resection was defined
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imaging, which was performed in ten patients with six
of them receiving MRI and four of them receiving CT
examinations using contrast agents. Ten patients did
not undergo postoperative imaging leaving the assess-
ment of resection extent to the surgeon. Tumor resec-
tion was declared incomplete in 3 of 7 patients by the
operating neurosurgeon due to clear infiltration of criti-
cal non-resectable structures. They had macroscopic
residual tumor, which in most cases infiltrated the
brainstem via the fourth ventricle. In 4 further incom-
plete tumor resections, cross sectional imaging identified
contrast-enhanced residual tumor tissue. Sixteen
patients had lateral tumor location (80%), whereas
4 patients (20%) presented with midline tumors. In all
patients complete staging of the craniospinal axis was
performed using MR-imaging as well as examination of
the cerebrospinal fluid (CSF).
In four patients intracranial or spinal dissemination
was present at primary diagnosis (20%). During surgery,
infiltration of the fourth ventricle was detected in
9 patients (45%). Out of these, a complete tumor resec-
tion was possible in 4 patients (44%). Eleven patients
did not show direct affection of the fourth ventricle, and
in this subgroup a complete resection was achieved in
9 patients (81.82%).
Neuropathological diagnosis was desmoplastic medul-
loblastoma in all patients according to the current clas-
sification criteria of the World Health Organization
(WHO) for medulloblastoma [19]. Based on the features
in hematoxyline/eosine and reticulin stained sections,
desmoplastic medulloblastoma was diagnosed when hav-
ing a biphasic architecture that consisted of regions with
dense intercellular reticulin and nodular reticulin-free
zones, within which tumor cells show a neurocytic phe-
notype (Figure 1).
Radiotherapy
Postoperative RT was conducted as CSI and a subse-
quent boost to the posterior fossa in all but two
patients. CSI was delivered with a median total dose of
35.2 Gy (range 23.4 - 36 Gy), and the boost to the pos-
terior fossa was applied up to a total median dose of
54.4 Gy (range 48 - 68 Gy). Median single doses were
1.63 Gy for CSI and 1.8 Gy for boost irradiation, and
ranged between 1 and 2 Gy. Boosts were applied with
conventional X-ray-based techniques in 11 patients,
while in 9 patients the boost was delivered using 3D-
treatment planning based on CT- and MR-imaging.
Treatment was delivered using 4 isocentric non-copla-
nar irregularly shaped fields formed by a multileaf colli-
mator in individual mask fixation.
Radiation was delivered with 60 cobalt units in three
patients, who were treated before 1991, and with linear
accelerators in 17 patients. In one patient, irradiated with
CSI and boost to the posterior fossa, helical intensity
modulated radiotherapy (IMRT) using the tomotherapy
technique was employed [20].
Two patients received whole brain radiotherapy
(WBRT) with doses of 36 Gy and 40 Gy, respectively,
followed by boosts to the posterior fossa with an addi-
tional 18 Gy and 8 Gy, respectively. One of these two
patients required addition of local spinal RT for meta-
stasis 42 months after WBRT.
Chemotherapy
In one patient, before initiation of RT chemotherapy
consisting of procarbazine, vincristine and methotrexate
was administered. In seven patients RT was combined
with chemotherapy, consisting of weekly infusions with
vincristine. Twelve patients were treated with adjuvant
chemotherapy after radiation with nine of them being
enclosed within or treated in analogy to multimodal
Figure 1 Neuropathological diagnosis of desmoplastic medulloblastoma. A: Rarefied nodules of reduced cellularity surrounded by densely
packed hyperchromatic cells (100× magnification; HE-staining). B: Dense intercellular reticulin and nodular reticulin-free zones (200×
magnification; TP-staining).
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tric Hematology and Oncology (GPOH, HIT-Studies).
One patient received a chemotherapy consisting of vin-
cristine and lomustine after completion of radiotherapy.
Adjuvant chemotherapy with alternating methotrexate
and a combination of methylprednisolone, vincristine,
cytarabin, cisplatin, dacarbacine, lomustine, procarbacine
and hydroxyurea (“8i n1 ”) was administered in one
patient, who after suffering from local tumor recurrence
was treated with various non-standard chemotherapy
regimens as individual salvage concepts. Another patient
without chemotherapy during first line treatment
received two cycles of carboplatin and etoposide after
locally relapsing disease. One further patient, who had
received adjuvant post-irradiation procarbazine, vincris-
tine, and methotrexate, was treated with “8i n1 ” after
developing local disease recurrence. One patient insisted
to have received adjuvant chemotherapy of unknown
regimen.
Statistical analysis
Event-free survival was calculated from initial diagnosis
until first relapse at any site or death from any cause.
Overall, local and distant progression-free survivals were
calculated in months from the date of surgery until the
first diagnosis of recurrent disease. Overall survival (OS)
was calculated from the date of primary diagnosis until
the last date of follow up or death of the patient. Local
and distant progression-free survival rates (LPFS and
DPFS) were calculated from the date of surgery until
the first imaging diagnosis of tumor relapse and were
displayed with the Kaplan-Meier method. Results are
displayed in% ± standard error of the mean (SEM).
Survival curves were compared between groups by the
log-rank test. All statistical analyses were performed
with a software tool, “Statistika 6.1”.
Results
Toxicity
Adjuvant RT was well tolerated and completed by all
patients within the planned time intervals. Acute radio-
genic toxicity was relatively mild. Most patients experi-
enced temporary tiredness, and reported tolerable
nausea and transient alopecia. Treatment-refractory
nausea with vomiting (n = 2; 10%) and severe fatigue
syndrome (n = 4; 20%) were rarely diagnosed.
More severe acute toxicity was related to the addition
of chemotherapy. In five patients (25%), four of whom
received chemotherapy, temporary leukocytopenia was
observed and required postponing of further chemother-
apy in three patients (15%). Only one patient, who did
not receive chemotherapy, developed leukocytopenia
during CSI. In this patient, boost irradiation was
initiated before completion of CSI, and CSI was
continued after boost application when blood values had
recovered. During adjuvant chemotherapy, two patients
reported severe abdominal pain and obstipation that
was diagnosed as subileus with spontaneous remission
in both cases (10%). Acute skin-related toxicity was
observed in two patients who suffered from retroauricu-
lar ulcerations (10%).
Chronic toxicity comprised peripheral neuropathy in
six patients, all of whom had been treated with conco-
mitant or adjuvant vincristine (30%). One patient, who
had received cisplatin in an adjuvant setting developed
massive ototoxicity and finally underwent cochlea
implant 16 years after tumor resection. Another patient,
whose adjuvant chemotherapy was changed from cispla-
tin to carboplatin due to acute tinnitus after only one
cisplatin administration, still was diagnosed with chronic
high pitch deafness.
Mental development was impaired in three patients
(15%), who had received RT without chemotherapy at
the age of 3, 7, and 11 years, respectively, however suc-
cessfully attended schools for mentally handicapped
children. One female patient went through a phase of
severe post-treatment depression that was related to
transient infertility. Hypothalamic-pituitary dysfunction
was ruled out in this case, yet detected in three other
pediatric patients (15%) and led to hypothyroidism, pub-
ertas tarda and retarded growth that required hormone
substitution.
One patient was diagnosed with having Li-Fraumeni
syndrome (LFS) several years after being treated for
medulloblastoma and developed further LFS-spectrum
tumors including intraabdominal atypical teratoid rhab-
doid tumor and myelodysplastic syndrome. Radiation-
associated osteosarcoma of the skull base occurred
seven years after RT in one patient, who had been trea-
ted at the age of seven years. This tumor was incomple-
tely resected and additionally irradiated with single
doses of 1.8 Gy delivering a total dose of 36 Gy. After
six years, this patient is alive and disease-free.
Survival
Thirteen patients are alive at the time of this analysis.
Follow-up examinations including neuroimaging were
conducted for a median of 59 months, during which
7 patients suffered from relapse of disease (35%). Five of
seven patients with relapsing disease died from medullo-
blastoma (71.4%). Both patients with recurrent disease,
for whom no dates of death are known, had developed
spinal metastases and were lost to further follow-up
briefly after diagnosis of relapse, indicating probable
death. None of 13 patients found disease-free after
initial treatment died within the follow-up time.
Event-free survival (EFS) was 68.3% (SEM 0.107) after
60 months (figure 2). OS was 80% (SEM 0.107) at
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60 months (Figure 4). DPFS was found to be 80% (SEM
0.103) after 60 months (Figure 5).
Patterns of relapse
Seven patients (35%) developed relapsing disease after a
median of 31 months (range 6 - 65 months). Four
patients (20%) suffered from second relapses and three
(15%) from third relapses after an additional median
time of 22 and 3 months, respectively. Five of seven first
relapses were local posterior fossa relapses, whereas two
were spinal, one being limited to single segments of the
thoracic spinal cord, another one extending from the
skull base throughout the cervical spinal cord. In two
out of five patients with locally recurrent disease, initial
neurosurgery had not been complete (40%) as opposed
to four incomplete resections in 13 recurrence-free
patients (30.77%).
After diagnoses of first relapses, 2 patients underwent
re-resection with adjuvant re-irradiation yielding an
additional progression-free survival of 6 and 7 months,
respectively. One patient was reirradiated only, and two
were administered multiagent chemotherapy according
to individual institutional protocols. In two patients,
only palliative supportive treatment was performed.
Five patients died during follow-up-examinations
(25%), including all four patients who had developed
second relapses and two, in whom incomplete neurosur-
gical tumor resection was performed during initial treat-
ment. Two patients with spinal recurrent disease were
Figure 2 Event-free Survival: EFS was 90.0% at 12 months, 85.0%
at 24 months, 68.3% at 60 months and 54.9% at 120 months
(Kaplan-Meier, n = 20).
Figure 3 Overall survival: OS was 94,4% at 12 months, 88,9% at
24 months, 80% at 60 months and 54,9% at 120 months (Kaplan-
Meier, n = 20).
Figure 4 Local progression-free survival. LPFS was 94,7% at
12 months, 83,9% at 24 months, 71,2% at 60 months, and 59,9% at
120 months (Kaplan-Meier, n = 20).
Figure 5 Distant progression-free survival. DPFS was 93,3% after
36 months and 83,3% after 60 months with no further recurrences
after 43 months (Kaplan-Meier, n = 20).
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side of Germany, the other one with extensive spinal
disease rejecting further antitumor therapy.
Prognostic factors
Metastatic disease at primary diagnosis did not predict
for poor OS, local or distant PFS. Also, age (21 ≥ versus
> 21, and 18 ≥ versus > 18), tumor localisation (medial
versus lateral), administration of chemotherapy (yes ver-
sus no), neither combined nor adjuvant to radiation,
and extent of resection (complete versus incomplete)
did not significantly alter OS, local or distant PFS (table
1, additional file 1). In univariate analyses, OS was sig-
nificantly decreased by the formation of local and spinal
metastases after initial therapy (p = 0.02). Additionally,
LPFS was significantly reduced in those patients devel-
oping spinal metastases (p = 0.01). Male sex predisposed
for better local control (p = 0.04), possibly owing to
only seven female patients included in this analysis,
among whom two did not complete CSI and che-
motherapy during first-line therapy. One had initially
been misdiagnosed with cerebellar metastases of
unknown origin, and another female patient had
presented in very poor condition not eligible for CSI
immobilisation.
We evaluated affection of the fourth ventricle in our
cohort based upon preoperative MRI neuroimaging and
surgical reports. Nine patients (45%) within our group
showed histologically confirmed tumor cell invasion into
the fourth ventricle or extensive distortion of the fourth
ventricle at primary diagnosis, indicative of direct tumor
infiltration. Patients with locally infiltrating tumors were
less likely to undergo complete tumor resection (44.4%
vs. 81.8%). Of those patients without tumor infiltration
of the fourth ventricle, 82% lived after a median follow-
up of 59 months, as opposed to 67% with initial tumor
infiltration. However, OS, local PFS, and distant PFS
were not significantly affected by the extent of ventricu-
lar infiltration (p > 0.05; table 1).
In our cohort, 70% of all patients received chemother-
apy, either prior to irradiation (5%), combined with
radiotherapy (35%) or in an adjuvant setting (60%). All
patients who had received combined radiochemother-
apy, also received adjuvant chemotherapy. Six patients
(30%) never entered any chemotherapy-containing ther-
apy protocol. Although, addition of chemotherapy did
not significantly influence OS as well as local and dis-
tant PFS, there seemed to be favorable results for those
patients who were administered combined and adjuvant
chemotherapy (p = 0.19; Figure 6).
All patients received RT after surgery. Most patients
underwent CSI with additional boosts; however, two
patients received whole brain irradiation with doses of
36 Gy and 40 Gy, respectively, followed by boosts to the
posterior fossa with an additional 18 Gy and 8 Gy,
respectively. One of these patients had initially been sus-
pected to suffer from cerebellar metastases of unknown
origin, and rejected the addition of spinal RT after histo-
logical confirmation of desmoplastic medulloblastoma.
This patient developed spinal metastases within
42 months after initial treatment which required addi-
tion of local RT. The patient suffered from three further
spinal relapses causing death after a total time period of
110 months. The other patient who received WBRT
instead of CSI presented with very low performance
status after tumor resection and was unable to tolerate
the time necessary for CSI immobilization; this patient
presented with local relapse 16 months after finishing
whole brain irradiation and died shortly afterwards.
Only in one patient, chemotherapy consisting of procar-
bazine, vincristine and methotrexate was administered
before initiation of radiotherapy. This patient ultimately
died from repeatedly relapsing disease 65, 101 and
124 months after primary diagnosis.
Table 1 Non-significant prognostic factors
Non-prognostic factors OS (p) LPFS (p) DPFS (p)
Primary metastatic disease 0.36 0.35 0.53
Infiltration of the fourth ventricle 0.45 0.33 0.8
Tumor location (lateral vs. medial) 0.48 0.29 0.53
Age (≤18 y vs. >18 y) 0.22 - 0.11
Age (≤21 y vs. >21 y) 0.5 0.73 0.62
Extent of resection (complete vs. partial) 0.43 0.97 0.19
Administration of chemotherapy 0.7 0.59 0.27
Statistical analysis revealed non-signficance for multiple prognostic factors on
OS, LPFS, and DPFS.
Figure 6 Local progression-free survival with adjuvant
radiotherapy versus radiochemotherapy (RCHT; concomitant
and adjuvant chemotherapy). The addition of chemotherapy
achieves favourable, but not yet significant results for local
progression-free survival (p = 0.19).
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In the present analysis, we evaluated therapy response
and outcome in 20 patients with desmoplastic medullo-
blastoma, who had received radiotherapy after tumor
resection in combination with or without chemotherapy.
We found high rates of EFS, OS, LPFS, and DPFS with
moderate toxicity in the majority of patients. In our
cohort, all patients received RT, but less than 50% were
administered chemotherapy according to pediatric pro-
tocols, still showing quite favorable results when com-
pared to other studies. Due to lack of standardized
protocols for the treatment of adults with medulloblas-
tomas, numerous individual treatment strategies for
non-pediatric patients have evolved that abandon com-
bined or adjuvant addition of chemotherapy and alter
dosage and fractionation scheme of RT. Our patients
with desmoplastic medulloblastoma turned out to profit
most from postoperative CSI with combined and adju-
vant chemotherapy and achieved good results also at
tumor stages that have been shown to predispose for
poor outcome in classical medulloblastoma. As opposed
to those rare patients with primary metastatic disease or
deep locoregional infiltration, in whom no significant
reduction of OS, LPFS, and DPFS was detected, the for-
mation of spinal metastases and locally recurrent disease
after completion of any sole or combined therapy signif-
icantly decreased these patients’ outcome. OS in relap-
sing disease was calculated to be 4 years, and not
yet reached in those patients with controlled disease
(p = 0.02).
In the era of risk adapted therapy approaches, predic-
tors of good and bad therapy response must be clearly
identified. Clinical parameters such as age, metastatic
stage at primary diagnosis, or extent of initial surgery
are useful for stratification of patients into low- and
high-risk medulloblastoma therapy groups and have pro-
ven efficacy in children with medulloblastoma [21-23].
Subclinical parameters such as histological analyses have
not yet been integrated into the process of therapy stra-
tification in the management of medulloblastoma. How-
ever, in desmoplastic histology variant, which has
repeatedly been suggested as a positive predictor, chro-
mosome 9q loss of heterozygosity (LOH) is quite exclu-
sively detected and cannot be found in classic histology,
providing independent evidence that desmoplasia may
indeed be pathogenetically distinct from its non-desmo-
plastic counterpart and therefore requires individual
therapy regimens based upon individual patterns of risk
factors [16,24].
The treatment of patients with medulloblastoma, espe-
cially in the adult population, is currently being evalu-
ated in clinical trials. This directs attention towards
desmoplastic histology, as it is a more frequent finding
in adult patients. In the present analysis of patients with
desmoplastic histology, most patients were adults, thus
displaying an appropriate cohort for future studies on
non-pediatric medulloblastoma patients who may not
have been sufficiently represented and analysed in for-
mer pediatric studies. Patients with desmoplastic histo-
logy have been discussed controversially with respect to
outcome compared to patients with classical medullo-
blastomas or supratentorial PNET [3,25-27]. Rutkowski
et al. have demonstrated desmoplastic histology to be an
independent and significant prognostic factor for favor-
able outcome in young children compared with classic
histology (10 years PFS 85% versus 34%) [16].
Several authors have looked for general differences
between pediatric and adult desmoplastic medulloblas-
toma, and have found that despite differing growth
rates, which they see as age-related factors, there are
major similarities concerning typical biochemical and
histological features of desmoplasia [11,28]. Independent
of patient age, probes are immunoreactive with markers
of neuronal commitment such as tubulines and neurofi-
laments; a more mature neuronal character in adult
desmoplastic medulloblastoma was detected [29]. How-
ever, since there are major clinical differences between
adult and pediatric patients concerning treatment-
related side effects, such as radiation-associated mental
impairment, a clear distiction must be made between
these two groups. Recent studies have proven efficacy of
intensive chemotherapies in young children under the
age of three, in whom CSI can possibly be avoided or at
least delayed in order to prevent neurological deficits
[30]. There were no children under the age of three in
this group.
Outcome observed in this analysis of mostly adult
patients compares well to published results on treatment
of both medulloblastoma in general and desmoplastic
medulloblastoma. OS rates for patients within multimo-
dal therapy regimens have previously been reported to
range from 50% to 70% at 60 months, and from 30% to
50% at 120 months [8,31,32]. In our cohort, OS at 60
months was 80%, and 54.9% at 120 months. In a retro-
spective analysis of 66 patients performed at the Depart-
ment of Radiooncology at the University Hospital of
Heidelberg, desmoplastic medulloblastoma patients fare
better than their classic counterparts, though statistical
significance was not yet reached due to small patient
numbers (OS at 5 years: 80 vs. 68%, p = 0.097) [33]. Simi-
lar to adult medulloblastoma in general, where 5 years of
local progression-free survival are reported in 67% [34],
posterior fossa control rates in our group of mostly adult
desmoplastic medulloblastoma reached 71.2%.
Desmoplastic histology may have been underestimated
as a predictor of good response due to its frequent
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chemotherapy is not as routinely administered as in
children despite possible contributions to better out-
come; however, it can be argued that addition of che-
motherapy may offer significant benefit also in the adult
population [35]. Due to the lack of standardized treat-
ments protocols for adult patients, chemotherapy is not
administered on a general basis in the adult population.
Combined and adjuvant chemotherapy was administered
in only 7 patients (35%) in the group reported here.
Treatment protocols evaluating the addition of com-
bined and adjuvant vincristine-based chemotherapy to
CSI have led to the conclusion that a reduction in CSI
doses from 35.2 to 23.4 Gy does not decrease survival
rates. However, lower doses of RT can help prevent
long-term treatment-associated adverse events [36,37].
In our group of patients, both acute and chronic ther-
apy-related toxicity was moderate, even though CSI
doses were reduced to 23.4 Gy in only four patients
(20%), all of whom were subjected to chemotherapy-
containing regimens. However, all patients who suffered
from chronic CNS toxicity such as pituitary gland failure
or cognitive impairment had received CSI doses of 36.0
Gy with additional boosts of 54.0 Gy and without che-
motherapy. On the contrary to radiogenic side effects,
chemotherapy-associated toxicity such as acute nausea,
and chronic peripheral neuropathy was documented in
up to 42% of the patients treated. Limited irradiation of
involved CNS areas may be a future option in pediatric
patients, but cannot be recommended in adult patients.
In our cohort, two adult patients did not receive CSI -
one due to misdiagnosis, the other one due to low per-
formance status. Both patients suffered from early
tumor relapses.
One secondary malignancy occurred seven years after
treatment and was an osteosarcoma of the skull base in
one pediatric male patient (5%). This tumor was treated
successfully with surgical resection and additional RT.
According to previous data, malignant bone tumors
after radiotherapy for medulloblastoma must be
expected in 7.4% of all patients [38], which emphasizes
the need for continuous follow-up examinations and
employment of less toxic regimens. In our case, the
patient had received a CSI dose of 35.2 Gy, a boost of
55 Gy in combination with concomitant and adjuvant
chemotherapy.
Administration of chemotherapy has been shown to
improve OS, LPFS and DPFS. In our cohort, addition of
chemotherapy did not influence therapy outcome signif-
icantly, which however may be due to the small number
of patients (n = 14), in whom chemotherapy was admi-
nistered [39]. Also, lack of significance may be attribu-
ted to the heterogeneity of chemotherapies used.
However, we did observe a trend towards better
outcome in those seven patients who received radiation
therapy in combination with weekly infusions of vincris-
tine and several adjuvant cycles of vincristine, lomustine
and carboplatin. None suffered from recurrent disease,
and LPFS appeared superior to regimens without
chemotherapy, though statistical significance was not yet
reached. Supporting the need for chemotherapy, none of
five patients dying from medulloblastoma in this cohort
h a dr e c e i v e dc o m b i n e da d j u v a n tr a d i o c h e m o t h e r a p y
(additional file 1).
In some reports, infiltration of the fourth ventricle,
especially of its floor, has been shown to possibly
enhance the risk of tumor dissemination. This is mainly
due to less probable complete resection and closer
proximity to spinal fluid circulation and, thus, imposes a
greater risk of distant and posterior fossa recurrence
and accounts for poor outcome [3,9]. However, the
statistical significance of locoregional tumor infiltration
as predictor of poor outcome remains controversial
[9,39], and our analysis did not detect any significant
impact on therapy response.
In several previous studies, both the initial spread and
dissemination of disease and postoperative tumor resi-
dues significantly determined outcome and prognosis in
patients with classic medulloblastoma [17,25,34]. In con-
trast, in our group of patients with desmoplastic medul-
loblastoma, outcome was influenced by the success of
combined first line therapies rather than the initial stage
of disease or extent of surgery. All patients with relap-
sing tumor either died from medulloblastoma or were
soon lost to further follow-up, most likely indicating
progression to death. On the contrary, initial locoregio-
nal infiltrative and metastatic disease or postoperative
residual tumor did not significantly influence outcome.
This finding, however, is limited by the fact that only
50% of the patients received postoperative cross-sec-
tional imaging, with 40% of them being subjected to CT
scans instead of MRI scan analysis, which is now known
to provide more reliable information about the extent of
resection. Being a rare diagnosis, the identification of
prognostic factors and their statistical evaluation is com-
promised by the small number of patients.
Conclusions
Tumor features at initial diagnosis such as lateral versus
medial location, infiltration of the fourth ventricle, meta-
static disease, extent of resection or age did not affect
therapy outcome in our cohort. This supports the inclu-
sion of patients with advanced disease in extensive treat-
ment protocols, still with curative intent. However,
treatment failure after first line regimens, such as spinal
recurrence of disease significantly impaired outcome.
Recurrence of disease occurred as late as 65 months
after completion of initial therapy, thus emphasizing the
Rieken et al. BMC Cancer 2010, 10:450
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Page 8 of 10need for continuous follow-up examinations over many
years. Radical surgery to a reasonable extent followed by
radiotherapy and both combined and adjuvant che-
motherapy according to pediatric protocols provide the
best results to date and are confirmed by our data. We
collected our data retrospectively and not from a con-
trolled investigator-blinded clinical study. Therefore,
future prospective studies are needed to confirm the
most effective combination of treatment modalities and
to clarify the role of desmoplastic histology as a prog-
nostic factor itself.
Additional material
Additional file 1: Patient characteristics. individual characteristics of
20 patients with histologically confirmed desmoplastic medulloblastoma.
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